Short Interest in Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Decreases By 96.9%

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the recipient of a large decline in short interest in the month of August. As of August 31st, there was short interest totalling 400 shares, a decline of 96.9% from the August 15th total of 12,900 shares. Based on an average trading volume of 154,300 shares, the short-interest ratio is presently 0.0 days.

Chugai Pharmaceutical Stock Up 4.4 %

Shares of OTCMKTS:CHGCY traded up $1.02 during midday trading on Friday, hitting $24.12. The company had a trading volume of 87,323 shares, compared to its average volume of 63,082. Chugai Pharmaceutical has a 12 month low of $13.85 and a 12 month high of $25.99. The firm has a fifty day simple moving average of $21.77 and a 200 day simple moving average of $18.91.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.22 EPS for the quarter. Chugai Pharmaceutical had a net margin of 32.68% and a return on equity of 21.45%. The business had revenue of $2.03 billion for the quarter. Equities research analysts expect that Chugai Pharmaceutical will post 0.78 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.